Astrazeneca Pharma India Ltd
₹
None%
- close price
About
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]
Key Points
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Dividend Payout % |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Equity Capital |
Reserves |
Total Liabilities |
CWIP |
Investments |
Total Assets |
Cash Flows
Figures in Rs. Crores
Net Cash Flow |
Ratios
Figures in Rs. Crores
Debtor Days |
Inventory Days |
Days Payable |
Cash Conversion Cycle |
Working Capital Days |
ROCE % |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
-
Board Meeting Outcome for Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
25 Sep - Appointment of Ms. Monica Widhani as Independent Director.
-
Increase In Volume
25 Sep - No information affecting price/volume behavior.
-
Clarification sought from AstraZeneca Pharma India Ltd
25 Sep - Exchange has sought clarification from AstraZeneca Pharma India Ltd on September 25, 2024, with reference to Movement in Volume.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015
23 Sep - AstraZeneca receives approval for Durvalumab in India.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
Aug 2023Transcript PPT
-
Aug 2022Transcript PPT
-
Aug 2021Transcript PPT
-
Sep 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
-
Dec 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
Sep 2018TranscriptNotesPPT
Part of AstraZeneca UK plc
The company is promoted by AstraZeneca plc, a multinational pharmaceutical and biotechnology company headquartered in England. It has a diverse portfolio in various disease areas and has been successful in developing and manufacturing the Oxford-AstraZeneca COVID-19 vaccine. AstraZeneca Pharmaceuticals AB holds 75% of the company's shareholding.[1] [2]